ARNA a Drug stock that should Rally big ahead of FDA decision.
ARNA's Lorcaserin is up on FDA approval decision on 9/16/2010
In July VVUS drug soared up 50% in the final 2 weeks ahead of FDA approval decision.
On Wednesday September 15 the very same panelists that will vote on Lorcaserin are likely to vote to withdraw Meridia from the market because it is associated with heart disease. The very next day they will see Lorcaserin data showing 1 and 2 year efficacy data without valvulopathy/heart disease isses. This data includes very detailed scans of the heart at baseline and months 3-6-12 for the one year data and additionally at months 18 and 24 for the two year data. Lorcaserin is not seen to cause any heart problems, but is shown to provide improvements in secondary risk factors such as blood pressure, glucose levels, heart rate